A bispecific antibody cotargeting human epidermal growth factor receptor 2 (EGFR2) and type I insulin-like growth factor receptor (IGF-IR) was generated by engineering trastuzumab (anti-EGFR2 antibody) and m590 (anti-IGF-IR antibody) and showed superior anti-tumor activity compared with monospecific antibodies (Chen et al., 2014). This evidence concerns the gene ERBB2 and neoplasm.